Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vivo evidence of effective complement modulation by TriFu in comparison to C5 inhibition and complement depletion.

Blood advances·2026
Same author

Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis.

RMD open·2026
Same author

Complement in brain and eye disease: shared mechanisms, convergent pathologies, and common therapeutic opportunities.

Mammalian genome : official journal of the International Mammalian Genome Society·2026
Same author

Modulation of immunoglobulin G oligomerization by variable domain glycans: A mechanism to regulate complement activation.

PNAS nexus·2025
Same author

The Alzheimer's disease-associated complement receptor 1 variant confers risk by impacting glial phagocytosis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Enhanced immunocompatibility and hemocompatibility of nanomedicines across multiple species using complement pathway inhibitors.

Science advances·2025
Same journal

Fast Generation of F(Ab')<sub>2</sub> Fragments From Human IgG Using Fc-Fused IgG-Degrading Enzyme.

European journal of immunology·2026
Same journal

Generation of Regulatory T Cells Against Islet Neoantigen.

European journal of immunology·2026
Same journal

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European journal of immunology·2026
Same journal

Special Issue: yEFIS 3rd Symposium.

European journal of immunology·2026
Same journal

CRISPR/Cas9-Mediated Gene Knockout Reveals a Nonredundant Role for p16<sup>INK4A</sup> in Controlling TCR-Dependent and Independent CD8 T Cell Expansion.

European journal of immunology·2026
Same journal

Induction of Humoral and Cellular Immunity After SARS-CoV-2 JN.1 Vaccination in Individuals With and Without Prior Infection.

European journal of immunology·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles.

Marco Mannes1, Wioleta M Zelek2, Leendert A Trouw3

  • 1Institute of Clinical and Experimental Trauma-Immunology, Ulm University Medical Center, Ulm, Germany.

European Journal of Immunology
|June 19, 2026
PubMed
Summary
This summary is machine-generated.

New complement therapies offer targeted treatments for diseases. Researchers are exploring precision approaches to improve efficacy and reduce risks associated with current systemic complement inhibitors.

Keywords:
complement systemcomplement therapeuticstargeted delivery

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Related Experiment Videos

Last Updated: Jun 20, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Area of Science:

  • Immunology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Systemic complement inhibitors have advanced treatment but present challenges like infection risk and off-target effects.
  • Many complement-mediated diseases necessitate long-term management, increasing healthcare burdens.
  • Targeting complement therapies to specific body compartments offers a promising avenue for precision medicine.

Purpose of the Study:

  • To review approved complement therapeutics and emerging preclinical strategies.
  • To highlight essential properties for targeted complement therapies, including administration routes, tissue penetration, specificity, and mechanism of action.
  • To explore both dampening and localized activation strategies for complement intervention.

Main Methods:

  • Review of approved complement therapeutics.
  • Analysis of preclinical data on novel complement intervention concepts.
  • Identification of key characteristics for targeted therapy development.

Main Results:

  • Approved systemic complement inhibitors show clinical success but have limitations.
  • Emerging concepts focus on organ-, tissue-, or cell-specific complement modulation.
  • Key properties for targeted therapies include administration route, penetration, specificity, and mode of action.

Conclusions:

  • Next-generation complement therapeutics hold significant potential for more precise and effective clinical outcomes.
  • Targeted complement intervention can overcome limitations of current systemic approaches.
  • Future strategies may involve both inhibiting and locally activating the complement system for therapeutic benefit.